Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Peginterferon Alfa-2b (SCH 054031) vs Glycyrrhizin in Interferon (IFN)-Treated Patients With Chronic Hepatitis C and F2/F3 Liver Fibrosis (P04773)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with chronic hepatitis C previously treated with interferon~* At least 20 years of age~* Liver fibrosis score rated as F2 or F3 based on the result of liver biopsy at screening~* Female patients willing to use contraception~* Body weight from 35.0 kg to 110.0 kg (inclusive)~* Positive for hepatitis C virus ribonucleic acid (HCV-RNA) by qualitative assay~* Patients who meet the following laboratory criteria:~  * Serum alanine aminotransferase (ALT) level: \>60 IU/L~ * Neutrophil count: \>=1,200/mm\^3~ * Platelet count: \>=100,000/mm\^3~ * Serum potassium level: \>=3.5 mEq/L~Exclusion Criteria:~* Patients who received interferon therapy within 90 days of Screening~* Patients who have received antiviral agents or antitumor agents, or immunomodulator therapy (including chronic glucocorticoids and radiotherapy) within 90 days of Screening (excluding local administration and topical use)~* Patients who have received other investigational drugs within 90 days of Screening~* Hepatitis B surface antigen (HBs)positive~* Antinuclear antibody titer of 1:320 or higher~* Creatinine level exceeding the upper limit of the reference range measured at screening test 2;~* Fasting blood glucose level of \>=126 mg/dL~* Patients on insulin therapy regardless of the fasting blood glucose level~* Patients who have a concurrent or past history of any of the following conditions: liver cirrhosis, liver failure, or liver carcinoma; hepatic encephalopathy, esophageal varices requiring treatment, or ascites; suicidal attempt or ideation; epileptic seizures requiring drug therapy; angina pectoris, heart failure, myocardial infarction or fatal arrhythmia; autoimmune disease (Hashimoto's disease \[chronic thyroiditis\], Crohn's disease, ulcerative colitis, rheumatoid arthritis, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, autoimmune hemolytic anemia, scleroderma, etc.); malignant tumors (it is permitted to register patients with at least 5 years after cure).~* Patients who concurrently have any of the following conditions: liver disease such as autoimmune hepatitis, alcoholic liver injury, and drug-induced hepatitis; hemophilia; depression or schizophrenia which requires treatment; hypertension which cannot be controlled by drug therapy or arrhythmia which requires treatment, chronic pulmonary disease; abnormal thyroid function that cannot be controlled by drug therapy; organ transplants (other than corneal, hair transplant, etc.); aldosteronism, myopathy, or hypokalemia.~* Patients with a history of hypersensitivity to interferon preparations or biological products such as vaccines~* Patients with a history of hypersensitivity to monoammonium glycyrrhizinate, glycine, or L-cysteine monohydrochloride;~* Women who are pregnant or lactating, and women in whom pregnancy cannot be ruled out based on the result of serum human chorionic gonadotropin (HCG) measurement at Screening

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PegIFN-2b (Type: EXPERIMENTAL): Participants receiving PegIFN-2b at 0.5 ug/kg subcutaneously (SC) once a week for up to 156 weeks.
- SNMC (Type: ACTIVE_COMPARATOR): Participants receiving SNMC 40 mL by intravenous (IV) injection or IV infusion 3 times weekly for up to 156 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).